This filing reports two measles deaths in Pennsylvania, highlighting a significant resurgence of the disease in the US. Prediction markets anticipate over 4,000 cases this year, suggesting a modest demand tailwind for vaccine manufacturers Merck and GSK, though not a major earnings catalyst.
Two unvaccinated individuals in Pennsylvania have died from measles, marking the state's first fatalities in 35 years and the first in the US this year. This event underscores a growing measles outbreak, with the national case count already the highest since 1991. Prediction markets are pricing in a high probability of over 4,000 cases this year, driven by low vaccination rates in certain communities like Lancaster County. For vaccine manufacturers Merck (MRK) and GSK (GSK), this outbreak represents a modest demand tailwind for their measles-containing vaccines, as Merck has previously noted similar boosts in sales during outbreaks. However, it's not expected to be a major earnings catalyst. The broader implication is the potential loss of the US's measles elimination status, which could have long-term public health and policy consequences.